Literature DB >> 18085465

Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge.

Mark B Abelson1, Dennis L Spangler, Arthur B Epstein, Francis S Mah, H Jerome Crampton.   

Abstract

Olopatadine 0.1% (Patanol) and olopatadine 0.2% (Pataday) ophthalmic solutions are topical ocular anti-allergic agents with antihistaminic and mast cell stabilizing properties. The efficacy of two doses of olopatadine 0.1% was compared to one dose of olopatadine 0.2% in the prevention of ocular itching associated with allergic conjunctivitis over 24 hours. This double-masked conjunctival allergen challenge (CAC) study found no significant difference in the mean itching scores between two drops of olopatadine 0.1% and one drop of olopatadine 0.2%. Both showed significant activity at the 24-hour time point and were statistically superior to placebo. No adverse events occurred while on drug therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18085465     DOI: 10.1080/02713680701736558

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  9 in total

Review 1.  Antihistamines in ocular allergy: are they all created equal?

Authors:  Mark B Abelson; James T McLaughlin; Paul J Gomes
Journal:  Curr Allergy Asthma Rep       Date:  2011-06       Impact factor: 4.806

2.  Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies.

Authors:  Arthur B Epstein; Peter T Van Hoven; Alan Kaufman; Warner W Carr
Journal:  Clin Ophthalmol       Date:  2009-06-02

Review 3.  Ocular itch associated with allergic conjunctivitis: latest evidence and clinical management.

Authors:  Stacey Ackerman; Lisa M Smith; Paulo J Gomes
Journal:  Ther Adv Chronic Dis       Date:  2016-01       Impact factor: 5.091

4.  Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%.

Authors:  Jack V Greiner; Kimberly Edwards-Swanson; Avner Ingerman
Journal:  Clin Ophthalmol       Date:  2011-01-13

5.  Treatment of allergic conjunctivitis with olopatadine hydrochloride eye drops.

Authors:  Eiichi Uchio
Journal:  Clin Ophthalmol       Date:  2008-09

6.  Efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge model.

Authors:  Gail Torkildsen; Abhijit Narvekar; Mark Bergmann
Journal:  Clin Ophthalmol       Date:  2015-09-14

7.  Ocular itch relief with alcaftadine 0.25% versus olopatadine 0.2% in allergic conjunctivitis: pooled analysis of two multicenter randomized clinical trials.

Authors:  Eugene B McLaurin; Nicholas P Marsico; Stacey L Ackerman; Joseph B Ciolino; Julia M Williams; Linda Villanueva; David A Hollander
Journal:  Adv Ther       Date:  2014-09-27       Impact factor: 3.845

8.  A multicenter evaluation of the efficacy and duration of action of alcaftadine 0.25% and olopatadine 0.2% in the conjunctival allergen challenge model.

Authors:  Stacey Ackerman; Francis D'Ambrosio; Jack V Greiner; Linda Villanueva; Joseph B Ciolino; David A Hollander
Journal:  J Asthma Allergy       Date:  2013-04-08

9.  Topical Olopatadine Hydrochloride versus Ketotifen Fumarate for Allergic Conjunctivitis.

Authors:  Dharmistha Patel; N Sarala; Narendra Panduranga Datti
Journal:  J Ophthalmic Vis Res       Date:  2018 Apr-Jun
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.